Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Accreditation Certification ISQua EEA

 
The Ministry of Public Health (MOPH) is proud to announce the reception of the prestigious Award by the International Society for Quality in Health Care – External Evaluation Association (ISQua EEA) for the Accreditation Standards of Hospitals in Lebanon 2022 Edition.

This development marks a crucial step forward for quality improvement and the enhancement of patient safety culture with internationally recognized standards.

Given the principal importance of improving healthcare management, quality of care, and patient safety in our hospitals, especially in these challenging times in Lebanon, we are committed to maintaining the accreditation process as an integral part of continuous healthcare improvement in Lebanon, with teams/trainers dedicated to improving care in hospitals, 44 trained surveyors and more than 500 health professionals from all hospitals in Lebanon currently being trained.

Special recognition goes to Dr. Walid Ammar for his leadership and guidance in transforming the hospital accreditation system in Lebanon.

We would like to extend our gratitude to Dr. Fadi El-Jardali and his team for their exceptional work in revising and improving the accreditation standards and tools. We also thank Dr. Ali Elhaj for his contributions during the initial phase of standards revision.

We are deeply grateful the financial support of AFD, to the Haute Autorité de Santé (HAS France) and all individuals who offered their advice and technical support, especially Dr. Bruno Lucet for his complete support during all the preparation process for the ISQua EEA certification.

We express our sincere appreciation to the Comité Technique d’Accréditation Hospitalière (CTAH) for their valuable feedback and suggestions, as well as the National Hospital Accreditation Committee (CNAH) including the main stakeholders: Ecole Supérieure des Affaires (ESA), Syndicate of Hospitals, Order of Physicians, Order of Nurses, Order of Pharmacists, Order of Midwives, Lebanese National Committee of Blood Transfusion, Army Medical Services, NSSF, MFE, and various faculties of medicine. We would like to acknowledge their contributions and their unwavering support.

Additionally, we extend our warm thanks to the national experts for their invaluable feedback and suggestions on the standards.

A special thanks to Perrine Malaud Wakim and the team of Pôle Santé at for their continuous dedication and support.

#Healthcare #Quality #Accreditation #Standards # Patient Safety Culture #MOPH #ESA #AFD #HAS #CNAH #CTAH #
    2
ATC Name B/G Ingredients Dosage Form Price
R01AA07 OTRIVIN MENTHOL 0.1% B Xylometazoline HCl - 0.1% 0.1% Drops 387,027 L.L
R01AA07 OTRIVIN B Xylometazoline HCl - 0.05% 0.05% Drops 181,419 L.L
S01AA13 OPTIFUCIN VISCOUS G Fusidic acid - 1% 1% Drops 208,296 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 2mcg/ml 2mcg/ml Drops solution 1,343,843 L.L
S01GX09 OLOPAT G Olopatadine (HCl) - 0.1% 0.1% Drops solution 524,099 L.L
S01GX09 OLOPAT UD G Olopatadine (HCl) - 0.1% 0.1% Drops solution 1,523,917 L.L
S02AA16 OFLOMED G Ofloxacin - 3mg/ml 3mg/ml Drops solution 317,403 L.L
S01AE01 OFLOX B Ofloxacin - 3mg/ml 0.3% Drops solution 366,869 L.L
S01AE01 OFLOX B Ofloxacin - 0.3% 0.3% Drops solution 366,869 L.L
S01CA01 OPTIDEX T G Dexamethasone - 1mg/ml, Tobramycin - 3mg/ml Drops suspension 266,081 L.L
S01AE01 OPTIFLOX G Ofloxacin - 3mg/ml 3mg/ml Drops suspension 143,791 L.L
M02AA15 OLFEN G Diclofenac sodium (diethylamine) - 1% 1% Gel 268,769 L.L
G03CA03 OESTRODOSE B Estradiol (17 bêta estradiol anhydre) - 0.06% 0.06% Gel 642,357 L.L
G03CA03 OESTRACLIN G Estradiol - 0.6mg/g 0.6mg/g Gel 448,843 L.L
S01BA01 OZURDEX B Dexamethasone - 700mcg 700mcg Implant 80,696,540 L.L
S01BA01 OZURDEX B Dexamethasone - 700mcg 700mcg Implant 80,696,540 L.L
L04AA36 OCREVUS BioTech Ocrelizumab - 300mg/10ml 300mg/10ml Injectable concentrate for solution 547,517,314 L.L
L01XA03 OXALIPLATIN HOSPIRA G Oxaliplatin - 100mg/20ml 5mg/ml Injectable concentrated solution 8,471,583 L.L
L01XA03 OXALIPLATIN EBEWE G Oxaliplatin - 50mg/10ml 50mg/10ml Injectable concentrated solution 3,405,297 L.L
L01XA03 OXALIPLATIN HOSPIRA G Oxaliplatin - 50mg/10ml 5mg/ml Injectable concentrated solution 3,450,988 L.L
B05BA10 OLIMEL N9E B Glucose solution - 27.5%, Amino acids solution - 14.2%, Lipid emulsion - 20%, Sodium - 70mmol/2l, Potassium - 60mmol/2l, Magnesium - 8mmol/2l, Calcium - 7mmol/2l, Phosphate - 30mmol/2l, Acetate - 107mmol/2l, Chloride - 90mmol/2l, Azote - 18g/2l Injectable emulsion 5,496,316 L.L
B02BD04 OCTANINE F BioHuman Plasma coagulation factor IX, human - 500IU 500IU Injectable freeze dried powder + diluent 31,425,075 L.L
L01FD01 OGIVRI BioTech Trastuzumab - 440mg 440mg Injectable lyophilised powder 80,027,615 L.L
L01XA03 OXALTIE G Oxaliplatin - 50mg 50mg Injectable lyophilised powder 2,957,797 L.L
L01XA03 OXALIPLATINO GP PHARM G Oxaliplatin - 100mg 100mg Injectable lyophilised powder for solution 6,199,145 L.L
L01XA03 OXALTIE G Oxaliplatin - 100mg 100mg Injectable lyophilised powder for solution 5,915,595 L.L
L01XA03 OXALIPLATINO GP PHARM G Oxaliplatin - 50mg 50mg Injectable lyophilised powder for solution 2,957,797 L.L
L01XA03 OXALTIE G Oxaliplatin - 50mg 50mg Injectable lyophilised powder for solution 2,957,797 L.L
B02BD02 OCTANATE BioHuman Coagulation Factor VIII - 250IU 250IU Injectable lyophilised powder for solution+diluent 13,247,110 L.L
B02BD02 OCTANATE BioHuman Coagulation Factor VIII - 500IU 500IU Injectable lyophilised powder for solution+diluent 26,495,478 L.L
    2
Sitemap
© Copyrights reserved to Ministry of Public Health 2025